Head-to-head evidence
CID-103 vs HLX15
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
CID-103
Developed by CASI Pharmaceuticals, Inc.
NCT04758767 · Phase 1 · completed
All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
HLX15
Developed by Shanghai Henlius Biotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT07477587 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CID-103's landscape · HLX15's landscape